ClinicalTrials.gg
CompletedNCT01874431ARTS-DNUpdated Jul 1, 2021Results posted

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

A Phase 2 interventional study of Finerenone (BAY94-8862) and Placebo in Diabetic Nephropathies, sponsored by Bayer. Completed at 147 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
823
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Enrollment
3rd of 10
823 · median 108
Started
2013
with 1 other
Phase 2
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
5 of 10
Bayer

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 1st registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.

03

Conditions studied

  • Diabetic Nephropathies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years and older.The lower age limit may be higher if legally required in the participating country
  • Women of can only be included in the study if a pregnancy test is negative and if they agree to use adequate when sexually active.
  • Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria

    • are on oral antidiabetics and / or insulin,
    • have a documented fasting glucose >/= 7.0 mmol/L in the medical history,
    • have a 2 hour plasma glucose >/=11.1 mmol/L during an oral glucose tolerance test in the medical history, or
    • have a (HbA1c) >/=6.5% [National Glycohemoglobin Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)] in the medical history or at the run-in visit
  • Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria:

    • Persistent very high albuminuria defined as urinary albumin-to-creatine ratio (UACR) of >/=300 mg/g ( >/= 34 mg/mmol) in 2 out of 3 first morning void samples and estimated (eGFR) >/=30 mL/min/1.73 m² but \< 90 mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL = milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or
    • Persistent high albuminuria defined as UACR of >/=30 mg/g but \<300 mg/g in (>/=3.4mg/mmol but \<34 mg/mmol) in 2 out of 3 first morning void samples and eGFR >/=30 mL/min/1.73 m² but \< 90 mL/min/1.73m²
  • Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit
  • Serum potassium \</= 4.8 mmol/L at both the run-in visit and the screening visit

Exclusion criteria

Exclusion Criteria:

  • Non-diabetic renal disease
  • (HbA1c) >12% at the run-in visit or the screening visit
  • UACR >3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the run-in visit or screening visit
  • Hypertension with mean sitting systolic blood pressure (SBP) >/=180 mmHg or mean sitting diastolic blood pressure (DBP) >/=110 mmHg at the run-in visit or mean supine SBP >/=160 mmHg or mean sitting DBP >/=100 mmHg at the screening visit
  • Subjects with a clinical diagnosis of heart failure with reduced (HFrEF) and persistent symptoms ( class II-IV) at the run-in visit
  • Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic
  • Dialysis for acute renal failure within the previous 6 months prior to the run-in visit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
823 participants (actual)

Study arms

  • Experimental
    Finerenone (BAY94-8862) (1.25 mg)

    1.25 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862)(2.5 mg)

    2.5 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862)(5 mg)

    5 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862)(7.5 mg)

    7.5 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862) (10 mg)

    10 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862) (15 mg)

    15 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Experimental
    Finerenone (BAY94-8862)(20 mg)

    20 mg dose oral once daily for 90 days

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Placebo

    Placebo oral dose once daily for 90 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of UACR at Day 90 to UACR at Baseline

    Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.

    Time frame: Baseline and Day 90±2

Secondary outcomes

  1. Change From Baseline to Day 90 in Serum Potassium

    Time frame: Baseline and Day 90±2

  2. Change From Baseline to Day 90 in eGFR

    An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

    Time frame: Baseline and Day 90±2

  3. Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)

    The Kidney Disease QOL \[KDQOL\]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" subscore was analyzed.

    Time frame: Baseline and Day 90±2

  4. Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)

    EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).

    Time frame: Baseline and Day 90±2

07

Results

Posted May 4, 2021

Participant flow

The study was conducted at 148 study centers in 23 countries, from 12 June 2013 (first participant, first visit) to 07 August 2014 (last participant, last visit). The randomization was stratified by region (Europe, North America, Asia, others \[Australia, Israel, and South Africa\]), and type of albuminuria at screening (very high or high albuminuria).

Participant flow — Overall Study
MilestoneFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Started9692100989812512094
Participants received treatment9692100979812511994
Completed908790919011411290
Not completed6510781184
Withdrew: Physician decision00100000
Withdrew: Adverse event54652823
Withdrew: Protocol violation11103211
Withdrew: Non-compliance00001010
Withdrew: Logistical difficulties00000010
Withdrew: Withdrawal by subject00121130
Withdrew: Sponsor decision00001000
Withdrew: Lost to follow-up00100000

Outcome measures

PrimaryRatio of UACR at Day 90 to UACR at Baseline

Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.

Time frame:
Baseline and Day 90±2
Reported as:
Least squares mean · Ratio
Ratio of UACR at Day 90 to UACR at Baseline
RatioFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Ratio of UACR at Day 90 to UACR at Baseline0.869 ± 0.7720.89 ± 0.7860.824 ± 0.730.739 ± 0.6530.708 ± 0.6270.63 ± 0.5630.585 ± 0.5230.938 ± 0.829
Statistical analysis
  • Finerenone (BAY94-8862) (1.25 mg) vs Placebo · t-test, 1 sided · p = 0.1973 · Least square mean ratio: 0.926 · 90% CI 0.799 to 1.074
  • Finerenone (BAY94-8862) (2.5 mg) vs Placebo · t-test, 1 sided · p = 0.2808 · Least square mean ratio: 0.949 · 90% CI 0.818 to 1.101
  • Finerenone (BAY94-8862) (5 mg) vs Placebo · t-test, 1 sided · p = 0.0723 · Least square mean ratio: 0.878 · 90% CI 0.758 to 1.017
  • Finerenone (BAY94-8862) (7.5 mg) vs Placebo · t-test, 1 sided · p = 0.0039 · Least square mean ratio: 0.787 · 90% CI 0.68 to 0.912
  • Finerenone (BAY94-8862) (10 mg) vs Placebo · t-test, 1 sided · p = 0.0009 · Least square mean ratio: 0.755 · 90% CI 0.651 to 0.875
  • Finerenone (BAY94-8862) (15 mg) vs Placebo · t-test, 1 sided · p = < 0.0001 · Least square mean ratio: 0.671 · 90% CI 0.584 to 0.772
  • Finerenone (BAY94-8862) (20 mg) vs Placebo · t-test, 1 sided · p = < 0.0001 · Least square mean ratio: 0.624 · 90% CI 0.542 to 0.718
SecondaryChange From Baseline to Day 90 in Serum Potassium
Time frame:
Baseline and Day 90±2
Reported as:
Least squares mean · millimole per liter
Change From Baseline to Day 90 in Serum Potassium
millimole per literFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Change From Baseline to Day 90 in Serum Potassium0.109 (0.030 to 0.187)0.123 (0.043 to 0.203)0.202 (0.122 to 0.282)0.127 (0.047 to 0.207)0.167 (0.087 to 0.248)0.238 (0.165 to 0.31)0.188 (0.116 to 0.259)0.002 (-0.077 to 0.081)
Statistical analysis
  • Finerenone (BAY94-8862) (1.25 mg) vs Placebo · t-test, 2 sided · p = 0.0428 · Least squares mean difference: 0.107 · 95% CI 0.003 to 0.21
  • Finerenone (BAY94-8862) (2.5 mg) vs Placebo · t-test, 2 sided · p = 0.0223 · Least squares mean difference: 0.121 · 95% CI 0.017 to 0.225
  • Finerenone (BAY94-8862) (5 mg) vs Placebo · t-test, 2 sided · p = 0.0002 · Least squares mean difference: 0.2 · 95% CI 0.096 to 0.305
  • Finerenone (BAY94-8862) (7.5 mg) vs Placebo · t-test, 2 sided · p = 0.0181 · Least squares mean difference: 0.125 · 95% CI 0.021 to 0.229
  • Finerenone (BAY94-8862) (10 mg) vs Placebo · t-test, 2 sided · p = 0.0019 · Least squares mean difference: 0.166 · 95% CI 0.061 to 0.27
  • Finerenone (BAY94-8862) (15 mg) vs Placebo · t-test, 2 sided · p = < 0.0001 · Least squares mean difference: 0.236 · 95% CI 0.137 to 0.334
  • Finerenone (BAY94-8862) (20 mg) vs Placebo · t-test, 2 sided · p = 0.0002 · Least squares mean difference: 0.186 · 95% CI 0.088 to 0.284
SecondaryChange From Baseline to Day 90 in eGFR

An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

Time frame:
Baseline and Day 90±2
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline to Day 90 in eGFR
mL/min/1.73m^2Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Change From Baseline to Day 90 in eGFR-2.364 ± -4.311-3.189 ± -5.164-2.497 ± -4.475-3.378 ± -5.341-4.192 ± -6.181-3.806 ± -5.563-4.024 ± -5.792-1.578 ± -3.53
Statistical analysis
  • Finerenone (BAY94-8862) (1.25 mg) vs Placebo · t-test, 2 sided · p = 0.5454 · Least squares mean difference: -0.786 · 95% CI -3.337 to 1.765
  • Finerenone (BAY94-8862) (2.5 mg) vs Placebo · t-test, 2 sided · p = 0.2186 · Least squares mean difference: -1.61 · 95% CI -4.177 to 0.957
  • Finerenone (BAY94-8862) (5 mg) vs Placebo · t-test, 2 sided · p = 0.4859 · Least squares mean difference: -0.918 · 95% CI -3.503 to 1.667
  • Finerenone (BAY94-8862) (7.5 mg) vs Placebo · t-test, 2 sided · p = 0.1677 · Least squares mean difference: -1.8 · 95% CI -4.358 to 0.759
  • Finerenone (BAY94-8862) (10 mg) vs Placebo · t-test, 2 sided · p = 0.0462 · Least squares mean difference: -2.613 · 95% CI -5.183 to -0.044
  • Finerenone (BAY94-8862) (15 mg) vs Placebo · t-test, 2 sided · p = 0.0705 · Least squares mean difference: -2.228 · 95% CI -4.643 to 0.187
  • Finerenone (BAY94-8862) (20 mg) vs Placebo · t-test, 2 sided · p = 0.048 · Least squares mean difference: -2.446 · 95% CI -4.869 to -0.022
SecondaryChange From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)

The Kidney Disease QOL \[KDQOL\]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" subscore was analyzed.

Time frame:
Baseline and Day 90±2
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)
scores on a scaleFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)-2.116 ± -4.5210.104 ± -2.369-1.229 ± -3.643-1.185 ± -3.597-2.596 ± -5.0490.112 ± -2.0540.058 ± -2.1460.747 ± -1.684
Statistical analysis
  • Finerenone (BAY94-8862) (1.25 mg) vs Placebo · t-test, 2 sided · p = 0.0757 · Least square mean difference: -2.863 · 95% CI -6.022 to 0.297
  • Finerenone (BAY94-8862) (2.5 mg) vs Placebo · t-test, 2 sided · p = 0.6941 · Least square mean difference: -0.643 · 95% CI -3.851 to 2.565
  • Finerenone (BAY94-8862) (5 mg) vs Placebo · t-test, 2 sided · p = 0.2228 · Least square mean difference: -1.976 · 95% CI -5.155 to 1.203
  • Finerenone (BAY94-8862) (7.5 mg) vs Placebo · t-test, 2 sided · p = 0.2313 · Least square mean difference: -1.932 · 95% CI -5.098 to 1.234
  • Finerenone (BAY94-8862) (10 mg) vs Placebo · t-test, 2 sided · p = 0.0386 · Least square mean difference: -3.342 · 95% CI -6.509 to -0.176
  • Finerenone (BAY94-8862) (15 mg) vs Placebo · t-test, 2 sided · p = 0.677 · Least square mean difference: -0.634 · 95% CI -3.624 to 2.355
  • Finerenone (BAY94-8862) (20 mg) vs Placebo · t-test, 2 sided · p = 0.6536 · Least square mean difference: -0.688 · 95% CI -3.699 to 2.322
SecondaryChange From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)

EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).

Time frame:
Baseline and Day 90±2
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)
scores on a scaleFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)Placebo
Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)1.381 ± -1.223.888 ± 1.2083.124 ± 0.4942.851 ± 0.2412.698 ± 0.0262.743 ± 0.3941.914 ± -0.4654.425 ± 1.794
Statistical analysis
  • Finerenone (BAY94-8862) (1.25 mg) vs Placebo · t-test, 2 sided · p = 0.0816 · Least square mean difference: -3.044 · 95% CI -6.471 to 0.383
  • Finerenone (BAY94-8862) (2.5 mg) vs Placebo · t-test, 2 sided · p = 0.7625 · Least square mean difference: -0.537 · 95% CI -4.027 to 2.953
  • Finerenone (BAY94-8862) (5 mg) vs Placebo · t-test, 2 sided · p = = 0.4603 · Least square mean difference: -1.301 · 95% CI -4.759 to 2.157
  • Finerenone (BAY94-8862) (7.5 mg) vs Placebo · t-test, 2 sided · p = 0.3678 · Least square mean difference: -1.574 · 95% CI -5.004 to 1.855
  • Finerenone (BAY94-8862) (10 mg) vs Placebo · t-test, 2 sided · p = 0.3279 · Least square mean difference: -1.727 · 95% CI -5.191 to 1.736
  • Finerenone (BAY94-8862) (15 mg) vs Placebo · t-test, 2 sided · p = 0.3102 · Least square mean difference: -1.682 · 95% CI -4.935 to 1.57
  • Finerenone (BAY94-8862) (20 mg) vs Placebo · t-test, 2 sided · p = 0.1317 · Least square mean difference: -2.511 · 95% CI -5.778 to 0.755

Adverse events

Collected over Up to approximately 93 days after the start of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone (BAY94-8862) (1.25 mg)0/96 (0%)5/96 (5.2%)14/96 (14.6%)
Finerenone (BAY94-8862)(2.5 mg)0/92 (0%)3/92 (3.3%)7/92 (7.6%)
Finerenone (BAY94-8862)(5 mg)0/100 (0%)7/100 (7%)13/100 (13%)
Finerenone (BAY94-8862)(7.5 mg)0/97 (0%)8/97 (8.2%)11/97 (11.3%)
Finerenone (BAY94-8862)(10 mg)0/98 (0%)2/98 (2%)10/98 (10.2%)
Finerenone (BAY94-8862)(15 mg)1/125 (0.8%)6/125 (4.8%)11/125 (8.8%)
Finerenone (BAY94-8862)(20 mg)0/119 (0%)4/119 (3.4%)12/119 (10.1%)
Placebo1/94 (1.1%)3/94 (3.2%)8/94 (8.5%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862)(2.5 mg)Finerenone (BAY94-8862)(5 mg)Finerenone (BAY94-8862)(7.5 mg)Finerenone (BAY94-8862)(10 mg)Finerenone (BAY94-8862)(15 mg)Finerenone (BAY94-8862)(20 mg)Placebo
HyperkalaemiaMetabolism and nutrition disorders2/960/921/1001/970/982/1252/1190/94
Blood potassium increasedInvestigations0/961/920/1001/970/982/1251/1190/94
Non-cardiac chest painGeneral disorders0/961/920/1000/970/980/1250/1190/94
Pancreatic enzymes increasedInvestigations0/961/920/1000/970/980/1250/1190/94
Local swellingGeneral disorders0/960/920/1000/970/980/1250/1191/94
Cerebrovascular accidentNervous system disorders0/960/920/1001/970/980/1250/1191/94
Ischaemic strokeNervous system disorders0/960/920/1000/970/980/1250/1191/94
Hypertensive crisisVascular disorders0/960/920/1000/970/980/1250/1191/94
HypoglycaemiaMetabolism and nutrition disorders1/960/920/1000/970/980/1250/1190/94
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/960/920/1001/970/980/1250/1190/94
Most frequent other events
Most frequent other events
EventFinerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862)(2.5 mg)Finerenone (BAY94-8862)(5 mg)Finerenone (BAY94-8862)(7.5 mg)Finerenone (BAY94-8862)(10 mg)Finerenone (BAY94-8862)(15 mg)Finerenone (BAY94-8862)(20 mg)Placebo
NasopharyngitisInfections and infestations7/964/928/1009/975/984/1258/1195/94
DizzinessNervous system disorders6/961/923/1001/973/985/1251/1192/94
DiarrhoeaGastrointestinal disorders5/962/924/1002/972/983/1255/1192/94

Baseline characteristics

Safety analysis set (SAF): all randomized subjects who took at least one dose of study drug and with data after beginning of treatment.

Age, Continuous
Age, Continuous(years)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean64.91 ± 9.5764.86 ± 9.0963.31 ± 8.7963.73 ± 10.0464.94 ± 9.6263.95 ± 8.3464.70 ± 9.2663.26 ± 8.6864.21 ± 9.15
Sex: Female, Male
Sex: Female, Male(Participants)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Female1814291821273025182
Male7878717977988969639
Baseline UACR
Baseline UACR(g/kg)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean412.02 ± 507.51471.01 ± 784.84402.04 ± 535.44405.14 ± 702.63441.16 ± 571.27450.12 ± 657.04379.28 ± 457.33377.28 ± 542.27417.16 ± 599.12
Baseline potassium
Baseline potassium(mmol/L)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean4.323 ± 0.4254.297 ± 0.4264.314 ± 0.3254.311 ± 0.4354.297 ± 0.4204.288 ± 0.4594.294 ± 0.4394.254 ± 0.4794.297 ± 0.427
Baseline eGFR
Baseline eGFR(mL/min/1.73m^2)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean66.113 ± 21.92367.425 ± 20.16467.080 ± 22.20567.497 ± 21.91767.042 ± 20.85767.455 ± 23.64666.039 ± 22.20572.213 ± 20.43467.544 ± 21.772
Baseline KDQOL-36 domain score (Effects of Kidney Disease)
Baseline KDQOL-36 domain score (Effects of Kidney Disease)(Scores on a scale)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean90.78 ± 10.2892.53 ± 9.5791.78 ± 12.5592.99 ± 11.0488.71 ± 16.5090.45 ± 14.3989.10 ± 17.4581.45 ± 20.4290.57 ± 13.69
Baseline EQ-5D scores (EQ5D - Visual Analog Scale)
Baseline EQ-5D scores (EQ5D - Visual Analog Scale)(Score on a scale)Finerenone (BAY94-8862) (1.25 mg)Finerenone (BAY94-8862) (2.5 mg)Finerenone (BAY94-8862) (5 mg)Finerenone (BAY94-8862) (7.5 mg)Finerenone (BAY94-8862) (10 mg)Finerenone (BAY94-8862) (15 mg)Finerenone (BAY94-8862) (20 mg)PlaceboTotal
Mean71.76 ± 16.3972.79 ± 14.8173.01 ± 16.2174.49 ± 15.9273.89 ± 16.4773.19 ± 16.1171.36 ± 17.4970.05 ± 17.6972.56 ± 16.42
08

Study locations

147 sites
  • Birmingham, Alabama 35294, United States
  • Chula Vista, California 91910, United States
  • Los Angeles, California 90022, United States
  • Los Gatos, California 95032, United States
  • New Haven, Connecticut 06510, United States
  • Miami, Florida 33015, United States
  • Pembroke Pines, Florida 33028, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612, United States
  • Flint, Michigan 48504, United States
  • Flushing, New York 11355, United States
  • Orangeburg, South Carolina 29118, United States
  • Chattanooga, Tennessee 37408, United States
  • Dallas, Texas 75235-3858, United States
  • Burlington, Vermont 05401, United States
  • St Leonards, New South Wales 2065, Australia
  • Clayton, Victoria 3168, Australia
  • Melbourne, Victoria 3052, Australia
  • Prahran, Victoria 3181, Australia
  • Reservoir, Victoria 3073, Australia
  • Box Hill, 3128, Australia
  • Woolloongabba, 4102, Australia
  • Graz, 3086, Austria
  • Innsbruck, 6020, Austria
  • Salzburg, 5020, Austria
  • Salzburg, 5026, Austria
  • St. Pölten, 3100, Austria
  • Wien, 1130, Austria
  • Haskovo, 6300, Bulgaria
  • Lukovit, 5770, Bulgaria
  • Plovdiv, 4002, Bulgaria
  • Ruse, 7003, Bulgaria
  • Sofia, 1431, Bulgaria
  • Stara Zagora, 6000, Bulgaria
  • Varna, 9000, Bulgaria
  • Varna, 9010, Bulgaria
  • Vancouver, British Columbia V5Z 1L8, Canada
  • Vancouver, British Columbia V6E 1M7, Canada
  • Courtice, Ontario L1E 3C3, Canada
  • Kitchener, Ontario N2H 5Z8, Canada
  • Scarborough, Ontario M1H 3G4, Canada
  • Toronto, Ontario M4C 5T2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Chrudim, 537 01, Czechia
  • Koprivnice, 742 21, Czechia
  • Krnov, 794 01, Czechia
  • Praha 2, 12808, Czechia
  • Aarhus C, 8000, Denmark
  • Gentofte, 2820, Denmark
  • Herlev, 2730, Denmark
  • Hillerød, DK-3400, Denmark
  • Holbaek, 4300, Denmark
  • Holstebro, DK-7500, Denmark
  • Kolding, 6000, Denmark
  • Helsinki, 00180, Finland
  • Jyväskylä, 40620, Finland
  • Oulu, 90100, Finland
  • Tampere, 33520, Finland
  • Turku, 20520, Finland
  • Amiens, 80000, France
  • La Tronche, 38700, France
  • Lyon Cedex, 69437, France
  • Paris Cedex 15, 75908, France
  • Strasbourg, 67091, France
  • Hannover, Niedersachsen 30625, Germany
  • Bad Oeynhausen, Nordrhein-Westfalen 32545, Germany
  • Düsseldorf, Nordrhein-Westfalen 40210, Germany
  • Ludwigshafen, Rheinland-Pfalz 67059, Germany
  • Neuwied, Rheinland-Pfalz 56564, Germany
  • Hong Kong, Hong Kong
  • Shatin, Hong Kong
  • Budapest, 1085, Hungary
  • Debrecen, 4032, Hungary
  • Eger, 3300, Hungary
  • Nagykanizsa, 8800, Hungary
  • Papa, 8500, Hungary
  • Ashkelon, 7830604, Israel
  • Holon, 5822012, Israel
  • Jerusalem, 9112001, Israel
  • Kfar Saba, 4428164, Israel
  • Petach Tikva, 4941492, Israel
  • Tel Aviv, 6203854, Israel
  • Tel Aviv, 6937947, Israel
  • Napoli, Campania 80131, Italy
  • Bergamo, Lombardia 24020, Italy
  • Bergamo, Lombardia 24127, Italy
  • Milano, Lombardia 20134, Italy
  • Milano, Lombardia 20157, Italy
  • Monza-Brianza, Lombardia 20832, Italy
  • Foggia, Puglia 71013, Italy
  • Cagliari, Sardegna 09134, Italy
  • Pisa, Toscana 56124, Italy
  • Padova, Veneto 35128, Italy
  • Busan, 49241, Korea, Republic of
  • Seoul, 03722, Korea, Republic of
  • Seoul, 06591, Korea, Republic of
  • AlMERE, 1311 RL, Netherlands
  • Eindhoven, 5600 PD, Netherlands
  • Groningen, 9713 GZ, Netherlands

Showing the first 100 of 147 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. PubMed 26325557 ↗
  • Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. PubMed 31583611 ↗
  • Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. PubMed 33107592 ↗
  • Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish. PubMed 33358451 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jul 2014, 12 months.

Results were first posted in May 2021, 6 years 9 months after primary completion. A results delay was requested in Jun 2015.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2013
First posted
Jun 11, 2013
StartActual
Jun 12, 2013
Primary completionActual
Jul 9, 2014
CompletionActual
Aug 7, 2014
Results delay requested
Jun 4, 2015
Results first posted
May 4, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01874431
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Jun 12, 2013
Primary completion
Jul 9, 2014
Completion
Aug 7, 2014
Results posted
May 4, 2021
Last update
Jul 1, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion